Immunosuppressive acidic protein and CA 125 levels in patients with ovarian cancer

Mauro Castelli, F. Battaglia, G. Scambia, P. Benedetti Panici, G. Ferrandina, A. M. Mileo, S. Mancuso, U. Ferrini

Research output: Contribution to journalArticlepeer-review

Abstract

The serum levels of immunosuppressive acid protein (IAP) and CA 125 were determined in 98 patients with ovarian cancer, in 20 patients with benign ovarian tumors and in a group of normal postmenopausal women as controls. On the basis of the mean values of normal controls (346.46±133.26 µg/ml), the IAP threshold was fixed at 613 µg/ml. Increased IAP levels were found in 70.4% of patients with ovarian cancer, in 25% of benign tumors and in 4.5% of normal women. Elevated levels of CA 125 were observed in 66.6% of cancers, in 40% of benign tumors and in 6.9% of controls. In particular, in early stage ovarian cancer the combined assay of the two markers increased by about 30% with respect to CA 125 alone. The simultaneous determination of IAP and CA 125 allowed an overall sensitivity of 84% without any significant reduction of specificity.

Original languageEnglish
Pages (from-to)13-17
Number of pages5
JournalOncology
Volume48
Issue number1
DOIs
Publication statusPublished - 1991

Keywords

  • CA 125
  • Immunosuppresive acidic protein
  • Ovarian cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Immunosuppressive acidic protein and CA 125 levels in patients with ovarian cancer'. Together they form a unique fingerprint.

Cite this